Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2015 (2015), Article ID 468675, 6 pages
http://dx.doi.org/10.1155/2015/468675
Review Article

Intravenous Iron Administration and Hypophosphatemia in Clinical Practice

Department of General Internal Medicine, Centres Hospitaliers Jolimont, 1400 Nivelles, Belgium

Received 29 January 2015; Revised 12 April 2015; Accepted 19 April 2015

Academic Editor: Bruce M. Rothschild

Copyright © 2015 S. Hardy and X. Vandemergel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. C. Looker, P. R. Dallman, M. D. Carroll, E. W. Gunter, and C. L. Johnson, “Prevalence of iron deficiency in the United States,” The Journal of the American Medical Association, vol. 277, no. 12, pp. 973–976, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Cote, M. D. Zilberberg, S. H. Mody, L. J. Dordelly, and B. Celli, “Haemoglobin level and its clinical impact in a cohort of patients with COPD,” European Respiratory Journal, vol. 29, no. 5, pp. 923–929, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. J. Bryant, Y. Y. Yau, S. M. Arceo, J. A. Hopkins, and S. F. Leitman, “Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome,” Transfusion, vol. 53, no. 8, pp. 1637–1644, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Vaucher, P.-L. Druais, S. Waldvogel, and B. Favrat, “Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial,” Canadian Medical Association Journal, vol. 184, no. 11, pp. 1247–1254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Lindgren, O. Wikman, R. Befrits et al., “Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study,” Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 838–845, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Bergwitz and H. Jüppner, “Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23,” Annual Review of Medicine, vol. 61, pp. 91–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203565s000lbl.pdf.
  8. X. Vandemergel and F. Vandergheynst, “Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature,” Case Reports in Endocrinology, vol. 2014, Article ID 843689, 5 pages, 2014. View at Publisher · View at Google Scholar
  9. A. Blazevic, J. M. Hunze, and J. M. M. Boots, “Severe hyposphosphatemia after intravenous iron administration,” Netherlands Journal of Medicine, vol. 72, no. 1, pp. 49–53, 2014. View at Google Scholar · View at Scopus
  10. L.-Y. Mani, G. Nseir, J.-P. Venetz, and M. Pascual, “Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient,” Transplantation, vol. 90, no. 7, pp. 804–805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. C. Fierz, R. Kenmeni, A. Gonthier, F. Lier, F. Pralong, and P. Coti Bertrand, “Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient,” European Journal of Clinical Nutrition, vol. 68, no. 4, pp. 531–533, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. P.-Y. Liu and C.-Y. Jeng, “Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure,” Journal of the Chinese Medical Association, vol. 67, no. 7, pp. 355–359, 2004. View at Google Scholar · View at Scopus
  13. S. B. De Oliveira Iglesias, H. Pons Leite, and W. B. De Carvalho, “Hypophosphatemia-induced seizure in a child with diabetic ketoacidosis,” Pediatric Emergency Care, vol. 25, no. 12, pp. 859–861, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Turnbull, D. Lumsden, A. Siddiqui, J.-P. Lin, and M. Lim, “Osmotic demyelination syndrome associated with hypophosphataemia: 2 cases and a review of literature,” Acta Paediatrica, vol. 102, no. 4, pp. e164–e168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. L. R. O'Connor, W. S. Wheeler, and J. E. Bethune, “Effect of hypophosphatemia on myocardial performance in man,” The New England Journal of Medicine, vol. 297, no. 17, pp. 901–903, 1977. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Ognibene, R. Ciniglio, A. Greifenstein et al., “Ventricular tachycardia in acute myocardial infarction: the role of hypophosphatemia,” Southern Medical Journal, vol. 87, no. 1, pp. 65–69, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Russell, “Osteomalacic myopathy,” Muscle and Nerve, vol. 17, no. 6, pp. 578–580, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. P. C. Singhal, A. Kumar, L. Desroches, N. Gibbons, and J. Mattana, “Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia,” American Journal of Medicine, vol. 92, no. 5, pp. 458–464, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Poesen, D. Dierickx, and P. Evenepoel, “Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient,” Transplant International, vol. 25, no. 2, pp. e27–e28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. L. Beard, “Iron biology in immune function, muscle metabolism and neuronal functioning,” Journal of Nutrition, vol. 131, no. 2, pp. 568–580, 2001. View at Google Scholar · View at Scopus
  21. N. J. Kassebaum, R. Jasrasaria, M. Naghavi et al., “A systematic analysis of global anemia burden from 1990 to 2010,” Blood, vol. 123, no. 5, pp. 615–624, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. R. P. Allen, S. Auerbach, H. Bahrain, M. Auerbach, and C. J. Earley, “The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia,” The American Journal of Hematology, vol. 88, no. 4, pp. 261–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. W. Wells, S. Lewis, J. R. Barton, and S. Corbett, “Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients,” Inflammatory Bowel Diseases, vol. 12, no. 2, pp. 123–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. E. Murray-Kolb, “Iron status and neuropsychological consequences in women of reproductive age: what do we know and where are we headed?” Journal of Nutrition, vol. 141, no. 4, pp. 747s–755s, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. Q. Zhou, G. Lu, A. Liu, and T. Kohno, “Extraskeletal myxoid chondrosarcoma in the lung: asymptomatic lung mass with severe anemia,” Diagnostic Pathology, vol. 7, article 112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Leung, R. B. Weiskopf, J. Feiner et al., “Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans,” Anesthesiology, vol. 93, no. 4, pp. 1004–1010, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. M. M. Wood and P. C. Elwood, “Symptoms of iron deficiency anaemia. A community survey,” British Journal of Preventive & Social Medicine, vol. 20, no. 3, pp. 117–121, 1966. View at Google Scholar · View at Scopus
  28. B. Favrat, K. Balck, C. Breymann et al., “Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study,” PLoS ONE, vol. 9, no. 4, Article ID e94217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Herfs, L. Fleitmann, and I. Kocsis, “Treatment of iron deficiency with or without anaemia with intravenous ferric carboxymaltose in gynaecological practices—a non-interventional study,” Geburtshilfe und Frauenheilkunde, vol. 74, no. 1, pp. 81–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Froessler, J. Collingwood, N. A. Hodyl, and G. Dekker, “Intravenous ferric carboxymaltose for anaemia in pregnancy,” BMC Pregnancy and Childbirth, vol. 14, article 115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Evstatiev, O. Alexeeva, B. Bokemeyer et al., “Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 11, no. 3, pp. 269–277, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. D. B. van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione, “Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial,” Obstetrics and Gynecology, vol. 110, no. 2, pp. 267–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. L. T. Goodnough, D. B. Van Wyck, A. Mangione, J. Morrison, P. E. Hadley, and J. A. Jehle, “Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial,” Transfusion, vol. 49, no. 12, pp. 2719–2728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Ponikowski, D. J. van Veldhuisen, J. Comin-Colet et al., “Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency,” European Heart Journal, vol. 36, no. 11, pp. 657–668, 2015. View at Publisher · View at Google Scholar
  36. W. Y. Qunibi, C. Martinez, M. Smith, J. Benjamin, A. Mangione, and S. D. Roger, “A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1599–1607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Charytan, M. V. Bernardo, T. A. Koch, A. Butcher, D. Morris, and D. B. Bregman, “Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study,” Nephrology Dialysis Transplantation, vol. 28, no. 4, pp. 953–964, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Cada, T. L. Levien, and D. E. Baker, “Ferric carboxymaltose,” Hospital Pharmacy, vol. 49, no. 1, pp. 52–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. Injectafer, American Regent, Shirley, NJ, USA, 2013.
  40. I. Macdougall, A. H. Bock, F. Carrera et al., “FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia,” Nephrology Dialysis Transplantation, vol. 29, no. 11, pp. 2075–2084, 2014. View at Publisher · View at Google Scholar
  41. O. Konijki, S. Fukaya, H. Kanou, T. Imamoura, T. Iwamoto, and M. Takasaki, “A case of hypophosphatemia induced by intravenous administration of saccharated ion oxide,” Nihon Ronen Igakkai Zasshi, vol. 10, pp. 805–810, 1994. View at Google Scholar
  42. Y. Shimizu, Y. Tada, M. Yamauchi et al., “Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia,” Bone, vol. 45, no. 4, pp. 814–816, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Berndt and R. Kumar, “Phosphatonins and the regulation of phosphate homeostasis,” Annual Review of Physiology, vol. 69, pp. 341–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Saito and S. Fukumoto, “Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism,” International Journal of Pediatric Endocrinology, vol. 2009, Article ID 496514, 2009. View at Publisher · View at Google Scholar
  45. H. S. Murer, “Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions,” Journal of the American Society of Nephrology, vol. 2, no. 12, pp. 1649–1665, 1992. View at Google Scholar · View at Scopus
  46. M. Wolf, T. A. Koch, and D. B. Bregman, “Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women,” Journal of Bone and Mineral Research, vol. 28, no. 8, pp. 1793–1803, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. B. H. Durham, F. Joseph, L. M. Bailey, and W. D. Fraser, “The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays,” Annals of Clinical Biochemistry, vol. 44, no. 5, pp. 463–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. B. J. Schouten, P. J. Hunt, J. H. Livesey, C. M. Frampton, and S. G. Soule, “FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2332–2337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Prats, R. Font, C. García, C. Cabré, M. Jariod, and A. M. Vea, “Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study,” BMC Nephrology, vol. 14, article 167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Wang, Y. Yoshiko, R. Yamamoto et al., “Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro,” Journal of Bone and Mineral Research, vol. 23, no. 6, pp. 939–948, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Sato and M. Shiraki, “Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy,” Endocrine Journal, vol. 45, no. 4, pp. 431–439, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Yamamoto, Y. Okada, H. Mori, S. Fukumoto, and Y. Tanaka, “Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide,” Internal Medicine, vol. 51, no. 17, pp. 2375–2378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. E. Williams, “Metabolic bone disease in the bariatric surgery patient,” Journal of Obesity, vol. 2011, Article ID 634614, 9 pages, 2011. View at Publisher · View at Google Scholar
  54. S. E. Williams and A. A. Licata, “Improved forearm bone mineral density after treatment with vitamin D3 in a patient 30 years after bariatric surgery,” Journal of Bone and Mineral Research, vol. 23, article s226, 2008. View at Google Scholar
  55. Z. H. Hoo and M. J. Wildman, “Intravenous iron among cystic fibrosis patients,” Journal of Cystic Fibrosis, vol. 11, no. 6, pp. 560–562, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Martin-Malo, A. Merino, J. Carracedo et al., “Effects of intravenous iron on mononuclear cells during the haemodialysis session,” Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2465–2471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Kumar, “Tumor-induced osteomalacia and the regulation of phosphate homeostasis,” Bone, vol. 27, no. 3, pp. 333–338, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. G. I. Baroncelli, B. Toschi, and S. Bertelloni, “Hypophosphatemic rickets,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 6, pp. 460–467, 2012. View at Publisher · View at Google Scholar · View at Scopus